PCSK9 and triple-A syndrome: The IVW modelrevealed that genetically constructed PCSK9 inhibition significantlyreduced the risk of AAA and CAVS (odds ratio (OR): 0.595, 95% CI: 0.4585–0.730,OR: 0.717, 95% CI: 0.635–0.810, respectively, p< 0.0055), whereasit did not yield a favorable outcome for TAA and AD.